SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is surging in community discussions as supporters rally behind recent ticker recovery and growing organic engagement. The community is actively pushing for a breakout, focusing on upcoming milestones and potential airdrops as they aim to establish the project within the broader meme coin ecosystem.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is currently surging as investors pivot toward the Base ecosystem, fueled by anticipation surrounding upcoming network events and a broader rotation of liquidity into decentralized exchanges. The community remains highly focused on the protocol's fee-generating utility and the long-term impact of its tokenomics model as traders position themselves for potential expansion in the coming cycles.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DRB is gaining traction as a high-conviction play within the Base ecosystem, with investors highlighting its unique link to AI-driven wealth and the narrative that Grok's own wallet holds the asset. The community is actively discussing the token's massive growth potential, often drawing comparisons to historical meme coin runs while emphasizing its status as an early-stage, under-the-radar opportunity.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending following the announcement that SanDisk will replace it in the Nasdaq-100, fueling community debate about the long-term impact of AI on incumbent SaaS workflows and valuation. Investors are actively discussing the stock's sharp decline, weighing institutional de-risking and AI disruption fears against the company's deeply embedded enterprise utility and potential for future stabilization.

Global X Funds - Global X Silver Miners ETF

The Global X Silver Miners ETF (SIL) is drawing intense investor attention as silver prices reach historic highs, driven by a persistent supply deficit and strong industrial demand for the metal in AI, solar, and EV sectors. Market participants are actively debating the decoupling between silver's spot price and mining equities, with many looking for a dramatic catch-up rally in miners as the broader precious metals sector experiences increased volatility and record-breaking volume.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is trending as investors gear up for the anticipated April 13th topline data readout from the Phase 2/3 OptimUM-02 trial evaluating Darovasertib and Crizotinib in metastatic Uveal Melanoma. The community is heavily focused on whether the Progression-Free Survival and Overall Response Rate results will meet the high bar required for an Accelerated Approval filing, with sentiment bolstered by strong institutional interest and the company's robust balance sheet.

Byrna Technologies, Inc. is a less-lethal self-defense technology company, which engages in the business of developing, manufacturing, and selling innovative less-lethal personal security solutions. It operates through the following geographical segments: the United States, South Africa, Europe, South America, and Asia, and Canada. The company was founded on March 1, 2005 and is headquartered in Andover, MA.

Byrna Technologies Inc

Byrna Technologies is trending as investors respond to significant production increases and rising demand for its non-lethal self-defense devices, fueled by a broader market interest in security-focused stocks. The community remains deeply divided, with some highlighting strong fundamental growth and retail expansion, while others voice concerns over short-selling volatility and the company's long-term competitive position.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is facing intense scrutiny and shareholder frustration as investors actively discuss the company's discounted merger agreement with Garda Therapeutics and the perceived undervaluation of its core assets. The community is heavily focused on the potential to block the acquisition through legal injunctions or by organizing voting blocks, as many feel the tender offer fails to reflect the company's true value and cash position.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

Sei is experiencing renewed community focus as investors track its potential as a high-performance Layer-1 blockchain, with active discussions centering on upcoming network upgrades and its growing role in real-world asset tokenization. Traders are debating the project's long-term utility versus its recent price volatility, while many remain optimistic about its capacity to capture institutional interest and scale within the DeFi ecosystem.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401jK is gaining momentum as a community-driven project that uses memes to challenge the traditional retirement system and advocate for financial independence. The community is actively discussing its grassroots narrative, focusing on IRL raids and educational content while positioning the token as a rebellious alternative to corporate savings plans.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prelude Therapeutics (NASDAQ:PRLD) Shares Up 4.3%  - Still a Buy?

Prelude Therapeutics (NASDAQ:PRLD) Trading 4.3% Higher - What's Next...

Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp

Citizens Jmp lifted their price target on shares of Prelude Therapeutics from $3.00 to $6.00 and gave the stock a "market outperform" rating in a report on Wednesday...

Prelude Therapeutics Earnings Report: Q4 Overview

Prelude Therapeutics (PRLD) Expected to Announce Earnings on Monday

Prelude Therapeutics (NASDAQ:PRLD) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest...

Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9% - Should You Sell?

Prelude Therapeutics (NASDAQ:PRLD) Stock Price Down 0.9% - What's Next...

<ul class="summary-bullets"><li>Prelude Therapeutics now anticipates dosing the first patient with PRT12396 by the second quarter of 2026.</li><li>The early stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.</li><li>The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.</li></ul> Shares of Prelude Therapeutics Incorporated (PRLD) closed 13% higher on Tuesday and edged up 2% after hours after the U.S. Food and Drug Administration (FDA) gave clearances to proceed with early-stage trials for its experimental drug PRT12396.PRT12396 is being developed for the treatment of patients with certain myeloproliferative neoplasms. Myeloproliferative neoplasms (MPNs) are a group of rare, slow-growing blood cancers where the bone marrow produces too many red blood cells, platelets, or certain white blood cells, often due to acquired genetic mutations, leading to symptoms like fatigue, itching, headaches, and bleeding or clotting issues.<h2 class="st-heading-2">Trial Design And Timeline</h2>Prelude Therapeutics <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/03/3231175/0/en/Prelude-Therapeutics-Receives-FDA-Clearance-of-Investigational-New-Drug-Application-IND-for-PRT12396-a-Mutant-selective-JAK2V617F-Inhibitor.html">anticipates</a> dosing the first patient with the drug by the second quarter of 2026. The company said that the FDA’s clearance marks the first milestone in its focus on certain programs that it outlined in the last quarter.“We look forward to advancing PRT12396 into the phase 1 study in patients with polycythemia vera and myelofibrosis in parallel,” said Kris Vaddi, Chief Executive Officer of Prelude. Both polycythemia vera and myelofibrosis are types of blood cancer.The early-stage trial will determine the safety, efficacy and pharmacokinetic profile of PRT12396.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PRLD stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.A Stocktwits user opined that the news might be a hint that the company is moving in the right direction.<stembedurl>https://www.stocktwits.com/Jaybird827/message/643826772</stembedurl>Another voiced optimism for the stock rising as high as $3.<stembedurl>https://www.stocktwits.com/moosegoose/message/643791216</stembedurl><a href="https://stocktwits.com/symbol/PRLD">PRLD stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-shares-garner-retail-attention-ahead-of-q4-earnings-report/cZb02YuR4mN">VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did PRLD Stock Surge 13% Today?

Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396. 

Equity

Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen

Wall Street Zen cut Prelude Therapeutics from a "buy" rating to a "hold" rating in a research note on Sunday...

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest...

Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1% - What's Next?

Prelude Therapeutics (NASDAQ:PRLD) Trading 2.1% Higher - Time to Buy...

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.24	--	--	N/A
Q4 '25	-$0.03	-$0.20	-566.67%	MISSED
Q3 '25	-$0.37	-$0.26	29.73%	BEAT
Q2 '25	-$0.44	-$0.41	6.29%	BEAT
Q1 '25	-$0.47	-$0.42	10.00%	BEAT

PRLD
Prelude Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest PRLD News

PRLDPrelude Therapeutics Inc